Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma

Ferdinando C M Cananzi, Satvinder Mudan, Mary Dunne, Nneka Belonwu, Angus G. Dalgleish

Research output: Contribution to journalArticle

Abstract

Background: The long-term prognosis of patients with stage IV aJcc melanoma is extremely poor. We have previously published short-term clinical outcome and immunological responses to a heat killed Mycobacterium vaccae-based vaccine. Results: In this study we report on a better than expected long-term survival (3-y Dss 29·6%, 5-y, and 7-y Dss both 23·9%) relative to historical controls in the patients who received the vaccine in these trials, published in 1999 and 2003. although the complete or partial response was only 10%, it was the remarkable response to other interventions upon relapse, such as surgery and radiotherapy followed by stable disease that was previously unexpected. Methods: We reviewed the outcome of 72 patients who were treated with M. vaccae for metastatic melanoma between January 1996 and July 2004. Conclusion: Given this remarkable outcome in stage IV metastatic melanoma and its lack of toxicity we propose that this would make a promising candidate for randomized trials for stage III fully resected melanoma.

Original languageEnglish
Pages (from-to)2427-2433
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume9
Issue number11
DOIs
Publication statusPublished - 2013

Fingerprint

Mycobacterium
Melanoma
Survival
Vaccines
Radiotherapy
Hot Temperature
Recurrence

Keywords

  • Long-term survival
  • Mycobacterial vaccine
  • Stage IV melanoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Medicine(all)

Cite this

Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma. / Cananzi, Ferdinando C M; Mudan, Satvinder; Dunne, Mary; Belonwu, Nneka; Dalgleish, Angus G.

In: Human Vaccines and Immunotherapeutics, Vol. 9, No. 11, 2013, p. 2427-2433.

Research output: Contribution to journalArticle

Cananzi, Ferdinando C M ; Mudan, Satvinder ; Dunne, Mary ; Belonwu, Nneka ; Dalgleish, Angus G. / Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma. In: Human Vaccines and Immunotherapeutics. 2013 ; Vol. 9, No. 11. pp. 2427-2433.
@article{57229e4ad6c146299d89e88b91c47df7,
title = "Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma",
abstract = "Background: The long-term prognosis of patients with stage IV aJcc melanoma is extremely poor. We have previously published short-term clinical outcome and immunological responses to a heat killed Mycobacterium vaccae-based vaccine. Results: In this study we report on a better than expected long-term survival (3-y Dss 29·6{\%}, 5-y, and 7-y Dss both 23·9{\%}) relative to historical controls in the patients who received the vaccine in these trials, published in 1999 and 2003. although the complete or partial response was only 10{\%}, it was the remarkable response to other interventions upon relapse, such as surgery and radiotherapy followed by stable disease that was previously unexpected. Methods: We reviewed the outcome of 72 patients who were treated with M. vaccae for metastatic melanoma between January 1996 and July 2004. Conclusion: Given this remarkable outcome in stage IV metastatic melanoma and its lack of toxicity we propose that this would make a promising candidate for randomized trials for stage III fully resected melanoma.",
keywords = "Long-term survival, Mycobacterial vaccine, Stage IV melanoma",
author = "Cananzi, {Ferdinando C M} and Satvinder Mudan and Mary Dunne and Nneka Belonwu and Dalgleish, {Angus G.}",
year = "2013",
doi = "10.4161/hv.25618",
language = "English",
volume = "9",
pages = "2427--2433",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Taylor and Francis Inc.",
number = "11",

}

TY - JOUR

T1 - Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma

AU - Cananzi, Ferdinando C M

AU - Mudan, Satvinder

AU - Dunne, Mary

AU - Belonwu, Nneka

AU - Dalgleish, Angus G.

PY - 2013

Y1 - 2013

N2 - Background: The long-term prognosis of patients with stage IV aJcc melanoma is extremely poor. We have previously published short-term clinical outcome and immunological responses to a heat killed Mycobacterium vaccae-based vaccine. Results: In this study we report on a better than expected long-term survival (3-y Dss 29·6%, 5-y, and 7-y Dss both 23·9%) relative to historical controls in the patients who received the vaccine in these trials, published in 1999 and 2003. although the complete or partial response was only 10%, it was the remarkable response to other interventions upon relapse, such as surgery and radiotherapy followed by stable disease that was previously unexpected. Methods: We reviewed the outcome of 72 patients who were treated with M. vaccae for metastatic melanoma between January 1996 and July 2004. Conclusion: Given this remarkable outcome in stage IV metastatic melanoma and its lack of toxicity we propose that this would make a promising candidate for randomized trials for stage III fully resected melanoma.

AB - Background: The long-term prognosis of patients with stage IV aJcc melanoma is extremely poor. We have previously published short-term clinical outcome and immunological responses to a heat killed Mycobacterium vaccae-based vaccine. Results: In this study we report on a better than expected long-term survival (3-y Dss 29·6%, 5-y, and 7-y Dss both 23·9%) relative to historical controls in the patients who received the vaccine in these trials, published in 1999 and 2003. although the complete or partial response was only 10%, it was the remarkable response to other interventions upon relapse, such as surgery and radiotherapy followed by stable disease that was previously unexpected. Methods: We reviewed the outcome of 72 patients who were treated with M. vaccae for metastatic melanoma between January 1996 and July 2004. Conclusion: Given this remarkable outcome in stage IV metastatic melanoma and its lack of toxicity we propose that this would make a promising candidate for randomized trials for stage III fully resected melanoma.

KW - Long-term survival

KW - Mycobacterial vaccine

KW - Stage IV melanoma

UR - http://www.scopus.com/inward/record.url?scp=84887415446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887415446&partnerID=8YFLogxK

U2 - 10.4161/hv.25618

DO - 10.4161/hv.25618

M3 - Article

C2 - 23863507

AN - SCOPUS:84887415446

VL - 9

SP - 2427

EP - 2433

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 11

ER -